Tirzepatide
Injection or ODT
Many people struggle to lose weight despite doing everything right. You may be eating better, staying active, and still feel stuck in the same cycle of losing and regaining weight. Hunger stays high, cravings return, and it becomes harder to stay consistent over time. Over time, this can make progress feel less predictable and harder to maintain.
Tirzepatide is part of a doctor-supervised program designed to support appetite regulation and provide a more structured, consistent approach under medical guidance.
Provider-directed dose and schedule
Is this treatment available in my state?
Injection: Not available in the following states: Alaska, Mississippi, New Jersey.
Oral: Not available in the following states: Alabama, Alaska, Arkansas, Mississippi, New Jersey.
How It Works
Tirzepatide works by acting on more than one pathway involved in appetite. It targets signals that influence hunger and how the body handles food. This broader activity may help reduce appetite while supporting more consistent intake patterns throughout the day. This may help reduce how often you think about food and make eating feel more controlled.
The program uses a structured dosing approach that is adjusted by a licensed provider based on your response. This helps guide use while aiming to limit unwanted effects.
Understanding Your Options
Both Semaglutide and Tirzepatide are used in structured, provider-reviewed programs designed to support appetite regulation.
Semaglutide works on a single pathway involved in hunger and fullness and is often selected by patients starting with GLP-1 treatment.
Tirzepatide works on multiple pathways related to appetite and may be chosen by those looking for a broader approach.
Both options follow a guided dosing plan and can be adjusted over time based on your response. Semaglutide is often selected as a starting point for patients new to GLP-1 treatment, while Tirzepatide may be considered for a broader pathway approach.
Why This Approach Works
Tirzepatide combines a multi-pathway approach with structured clinical guidance. Instead of relying on trial and error, dosing and progression are adjusted based on your response. This helps create a more controlled and consistent process over time.
Who It May Be For
Adults struggling with ongoing hunger or cravings
Weight loss that is inconsistent or hard to maintain
Frequent food focus throughout the day
Looking for a structured medical approach
Prefer guidance from a licensed provider
Support & Ongoing Care
With RestartRX®, you are not managing this process on your own. A licensed provider reviews your plan, and support is available if adjustments are needed. You will receive clear guidance on dosing, use, and next steps.
Product Options
Typical Dosing Overview
Your provider determines your starting dose and any adjustments based on your history and response.
One price for every prescribed injectable dose within your selected medication and plan. Complete a short assessment before each refill. Treatment and refills require provider approval.
ODT Option
Orally disintegrating tablets dissolve in the mouth as a non-injection option.
Used once daily as part of a provider-reviewed plan.
Concentration Details
For injections, your provider selects the dose, concentration, and vial size for your prescribed plan.
The oral option uses Tirzepatide ODT in provider-selected 3 mg, 4 mg, or 5 mg strengths.
Selection Guidance
Choose your preferred form. Your provider selects the dose and any adjustments. Injectable plans use 4-week (28-day) treatment cycles. Oral purchase options remain one-time purchase or Auto-Refill with 30-day supplies. Recurring plans follow the billing schedule shown at checkout.
Formulation Notes
These options are compounded formulations prepared by a licensed pharmacy for an individual patient when clinically appropriate.
Tirzepatide may be provided as a subcutaneous injection or an orally disintegrating tablet (ODT). Some injection options include glycine and vitamin B12 as part of the formulation.
The compounded options offered here are not FDA-approved as specific drug products. Tirzepatide ODT is not FDA-approved. Your provider will determine the appropriate formulation and dose based on your medical history and treatment plan.
Safety Summary
Tirzepatide (Injection)
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
- Injection-site irritation
Do Not Use If
You have a personal or family history of medullary thyroid cancer (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or a prior serious allergy to tirzepatide or its ingredients.
Serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe allergic reaction, and possible thyroid C-cell tumors. See full safety information.
This compounded formulation is not FDA-approved as a specific drug product. Treatment requires review by a licensed clinician. Not all patients will qualify. This information does not replace medical advice.
Full Medication Safety Information
Active Ingredient
Tirzepatide
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
- Injection-site irritation
Serious Risks
- Pancreatitis
- Gallbladder disease
- Kidney injury related to dehydration
- Severe allergic reaction
- Possible thyroid C-cell tumors
Who Should Not Use
- Personal or family history of MTC
- MEN2 syndrome
- Prior serious allergy to tirzepatide or its ingredients
Important Warnings
Tirzepatide slows stomach emptying and may affect oral medicines, anesthesia, or sedation. Tell your clinician about all medications, pregnancy or plans for pregnancy, and upcoming procedures.
FDA Status
The compounded formulation offered here is not FDA-approved as a specific drug product.
Tirzepatide (ODT)
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
Do Not Use If
You have a personal or family history of medullary thyroid cancer (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or a prior serious allergy to tirzepatide or its ingredients.
Serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe allergic reaction, and possible thyroid C-cell tumors. See full safety information.
Tirzepatide ODT is compounded and is not FDA-approved as a specific drug product. Treatment requires review by a licensed clinician. Not all patients will qualify. This information does not replace medical advice.
Full Medication Safety Information
Active Ingredient
Tirzepatide
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
Serious Risks
- Pancreatitis
- Gallbladder disease
- Kidney injury related to dehydration
- Severe allergic reaction
- Possible thyroid C-cell tumors
Who Should Not Use
- Personal or family history of MTC
- MEN2 syndrome
- Prior serious allergy to tirzepatide or its ingredients
Important Warnings
Tirzepatide slows stomach emptying and may affect oral medicines, anesthesia, or sedation. Tell your clinician about all medications, pregnancy or plans for pregnancy, and upcoming procedures.
FDA Status
Tirzepatide ODT is compounded and is not FDA-approved as a specific drug product.
Start with a simple RestartRX medical review to see if this program is appropriate for you.